natgillin/translations-raw huggingface dataset:
The segregating step can have, on its inlet side, an upstream face that is substantially perpendicular to the portion of the step that defines the downstream portion of the channel. 
Uređaj prema jednom od patentnih zahtjeva 1 do 7, pri čemu stupanj odvajanja ima uzvodnu prednju stranu na svojoj ulaznoj strani koja je uspravna na dio stupnja koji definira nizvodni dio.
A host cell comprising the polynucleotide or polynucleotides of claim 6 or the vector or vectors of claim 7; or 
polinukleotid ili polinukleotide u skladu s patentnim zahtjevom 6, ili vektor ili vektore u skladu s patentnim zahtjevom 7; ili
A compound of the formula 
1. = Spoj s formulom R2
A compound of structure 6: 
Spoj, naznačen time, da je to spoj strukture 6:
An article of manufacture comprising a composition effective to treat an HCV infection or to inhibit the NS5B polymerase of HCV and packaging material comprising a label which indicates that the composition can be used to treat infection by the hepatitis C virus, wherein said composition comprises a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Predmet proizvodnje, naznačen time, da obuhvaća sastav učinkovit za liječenje HCV-infekcije ili za inhibiciju NS5B-polimeraze od HCV-a te pakirni materijal koji sadrži etiketu koja naznačava da se sastav može upotrebljavati za liječenje infekcije od virusnog hepatitisa C, pri čemu spomenuti sastav obuhvaća spoj prema jednom ili više od zahtjeva 1 do 11 ili njegovu farmaceutski prihvatljivu sol ili njegov ester.
comprising a microcontroller for generating a difference signal of the shear stress signals emitted by the signal-processing units. The axle-counting device according to claim 14, wherein the fiber Bragg gratings are attached to the rail in parallel with one another at an angle of from ±30° to ±60°, in particular ±45°, with respect to the neutral fiber. 
Uređaj za brojanje osovina prema jednom od zahtjeva od 10 do 16, naznačen time, da su Braggove rešetke (FBG1, FBG2) u vlaknu postavljene paralelno jedna u odnosu na drugu pod kutom od ±30° do ±60°, naročito pod kutom od ±45° u odnosu na neutralno vlakno (NF) na tračnici (T).
A compound structurally represented by formula: wherein 
Spoj strukturno prikazan formulom:
a method of treating or preventing cancer relapse in a subject, the method comprising administering to the subject a therapeutically effective amount of the first agent and the one or more second agents; 
liječenju relapsa raka u subjekta, koje obuhvaća primjenu terapijski učinkovite količine spoja formule VIII subjektu; ili
The pharmaceutical composition of claim 20, wherein the second therapeutic agent is an antibody or an anti-fibrotic agent. 
Protutijelo ili njegov za antigen vezni fragment za uporabu u postupku prema zahtjevu 15, gdje je drugo terapijsko sredstvo protutijelo ili kemoterapijsko sredstvo.
System according to claim 4, wherein the winding of one or each unit is integral with a bell-shaped element connected via a rigid arm to said point. 
Sustav prema patentnom zahtjevu 6 ili 7, naznačen time da je namotaj jedne ili svake jedinice integralan s elementom u obliku zvona (44, 54) koji je putem krute ruke (80, 82) povezan s navedenom točkom.
Typical protecting groups are well know and appreciated in the art Protecting Groups in Organic Synthesis, 3rd edition Theodora Greene, Peter Wuts (Wiley-Interscience) 1999. 
Uobičajene zaštitne skupine dobro su poznate i prihvaćene u struci (Theodora Greene, Peter Wuts: "Protecting Groups in Organic Synthesis", 3. izdanje (Wiley-Interscience), (1999.).
The pharmaceutical composition of claim 7 for use in the treatment or prevention of a hemoglobinopathy. The pharmaceutical composition of claim 7 for use in a method of treating or preventing a hemoglobinopathy in a patient in need of an increase in globin gene expression, the method comprising administering to the patient the pharmaceutical composition in an amount sufficient to increase the globin gene expression in the patient. 
Farmaceutski sastav prema patentnom zahtjevu 5, za upotrebu u postupku liječenja ili prevencije hemoglobinopatije kod pacijenta kome je potrebno povećanje ekspresije globinskog gena, postupka koji se sastoji od primjene farmaceutskog sastava pacijentu, u količini dovoljnoj da se poveća ekspresija globinskog gena kod pacijenta, opcionalno gdje je hemoglobinopatija talasemija ili anemija srpastih stanica kao što je B-talasemija.
The multi-armed polymer prodrug of claim 2, which comprises a 20 kilodalton four-arm PEG. 
Višestruko razgranati polimerni prolijek iz patentnog zahtjeva 2, koji sadrži četverograni PEG od 20 kilodaltona.
In some implementations, the airfoil-shaped profiles, which may form an opening therethrough, are made of a material such as wood, plastic, resins, composites, carbon materials, formed sheet metal, and the like. 
Fleksibilno krilo (20) prema Zahtjevu 12, gdje je svaki od većeg broja aerodinamično oblikovanih profila (30) izrađen od materijala odabranog iz grupe koja sadrži drvo, plastiku, smole, kompozite, ugljične materijale 1 materijale iz formiranih listova.
The computer implemented method of claim 1, wherein repairing the invalid field includes disabling, by the computing device, the invalid field. 
Postupak kojeg provodi računalo u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje usklađivanje, od strane računalnog uređaja, ispravljene prijenosne izvršne datoteke.
is selected from CH3, CH2D, CHD2, and CD3, wherein any atom not designated as deuterium in the compound is present at its natural isotopic abundance, 
Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema patentnom zahtjevu 1, gdje je bilo koji atom koji nije označen kao deuterij, prisutan kao izotop koji je najčešći u prirodi.
Use according to claim 1 or claim 2, wherein the composition is capable of inducing an immune response against rotavirus infection from at least three of the non-G1 rotavirus serotypes selected from the group consisting of: G2, G3, G4 and G9 serotypes. 
Upotreba u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što pripravak može potaknuti imunosni odgovor protiv infekcije rotavirusom od strane najmanje tri od serotipova rotavirusa koji nisu G1 i bira ih se iz skupine koju čine: serotipovi G2, G3, G4 1 G9.
In this way, the base station apparatus transmits the RRC signaling including information (keeping value) indicating a certain amount of resources in which the reception quality information can be mapped. 
Komunikacijski postupak prema zahtjevu 5, naznačen time da postupak nadalje obuhvaća: prijem, od uređaja bazne stanice (100), RRC signalizacije koja sadrži informacije koje ukazuju na unaprijed definiranu količinu resursa u kojima se mogu mapirati informacije o kvaliteti prijema.
and/or a physiologically acceptable salt thereof. 
i/ili njihova fiziološki prihvatljiva sol.
Moreover, in the case of such large products, applying the air-tight covering - typically a flexible foil - in the traditional manner takes much time and the covering material can only be used a single time, which entails rather a lot of waste. 
Osim toga, u slučaju tako velikih proizvoda, stavljanje neprodušnog pokrova - tipično savitljive folije - na tradicionalan način oduzima mnogo vremena i pokrovni materijal se može upotrijebiti samo jednom, što povlači za sobom prilično mnogo otpada.
A zinc finger protein (ZFP) that binds to an EPSPS target genomic region of interest, the ZFP comprising one or more zinc finger binding domains, wherein the ZFP comprises the recognition helix regions shown in a single row of Table A. 
Protein cinkovi prsti (ZFP), naznačen time, da se veže na ciljano genomsko područje od interesa EPSPS, gdje ZEP sadrži jednu ili više domena za vezanje cinkovih prstiju, pri čemu ZFP sadrži prepoznatljiva heliks- područja prikazana u jedinom redu u Tablici A.
The ingredients of part A were mixed with the exception of the Pemulen. 
Sastojci dijela A se pomiješaju uz izuzetak Pemulena.
The humanized anti-human a9 integrin antibody according to claim 1, wherein the heavy-chain constant region of the antibody is human IgY1 and the light-chain constant region of the antibody is human Igk. 
Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da konstantno područje jakog lanca od protutijela je humani Igy1 a konstantno područje slabog lanca od protutijela je humani Igk.
A mixed fungicidal composition containing the acid amide derivative or a salt thereof as defined in any one of the above (1) to (32), and another fungicidally active ingredient compound, as active ingredients. 
Kombinirani fungicidni pripravak, naznačen time, da kao djelatne sastojke sadrži derivat amida kiseline formule (I) ili njegovu sol, kako je definiran patentnim zahtjevom 1 i drugi fungicidni djelatni spoj.
The method according to claim 1, wherein the method further comprises adding one or more additional compounds or liquids to one or more of: the starting liquid of step a), the liquid obtained in step c), the AX-REED liquid, and/or the beverage. The method according to claim 1, wherein the method further comprises incubating the AX-REED liquid with one or more micro-organisms. The method according to claim 1, wherein the removal of anions of step d) comprises 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što postupak obuhvaća dodatni korak f), pri čemu korak f) sadrži dodavanje jednog ili više dodatnih spojeva u početnu tekućinu i/ili u tekućinu AX-REED i/ili u tekućinu tijekom postupka i/ili u napitak i/ili postupak nadalje obuhvaća korak g) dodavanje jedne ili više dodatnih tekućina u tekućinu AX-REED, tekućinu CX-REED ili tekućinu REED, te se tako dobiva napitak.
The method according to claim 21, wherein the antibody comprises a heavy chain wherein the variable domain comprises a CDR having the sequence given in SEQ ID NO:1 for CDRH1, SEQ ID NO:2, for CDRH2 and SEQ ID NO:3 for CDRH3 and a light chain wherein the variable domain comprises a CDR having the sequence given in SEQ ID NO:4 for CDRL1, SEQ ID NO:5 for CDRL2 and SEQ ID NO:6 for CDRL3. 
Postupak prema patentnom zahtjevu 21, pri čemu antitijelo sadrži teški lanac gdje varijabilna domena sadrži CDR koji ima sekvencu danu u SEQ ID NO:1 za CDRHI, SEQ ID NO:2, za CDRH2 i SEQ ID NO:3 za CDRH3 i laki lanac pri čemu varijabilna domena sadrži CDR koji ima sekvencu danu u SEQ ID NO:4 za CDRLI, SEQ ID NO:5 za CDRL2 i SEQ ID NO:6 za CDRL3.
Inhibition of MMPs provides a means for treating disease states wherein inappropriate metalloprotease activity results in degradation of connective tissue and inflammation. 
Inhibiranje MMP osigurava način liječenja bolesnih stanja u kojima neodgovarajuća aktivnost metaloproteaza uzrokuje razgradnju vezivnog tkiva i upalu.
Kit for use in two-step perioperative therapy as described in claim 1, containing a set of separate containers, in which the first container contains an avidin compound, selected from the group consisting of avidin, streptavidin, their polymeric derivatives and their derivatives with polyethylene glycol; and a second container contains a biotin compound bearing an anticancer agent. 
Komplet namijenjen upotrebi u perioperativnoj terapiji u dva koraka u skladu s patentnim zahtjevom 1, naznačen time što sadrži više odvojenih spremnika, gdje prvi spremnik sadrži avidinski spoj, kojeg se bira iz skupine koju čine avidin, streptavidin, njihovi polimerni derivati 1 njihovi derivati s polietilen-glikolom, a drugi spremnik sadrži biotinski spoj, koji nosi sredstvo protiv raka,
A method of modifying a target DNA, the method comprising contacting the target DNA with a complex comprising: 
Postupak modificiranja ciljane DNA, naznačen time što se postupak sastoji u stavljanju u kontakt ciljane DNA s kompleksom koji sadrži:
Figure 1c depicts the magnetic field simulation of a device disclosed in the prior art (WO 02/90002 A2, p. 
Na Slici lc prikazana je simulacija magnetskog polja uređaja opisanog u stanju tehnike (WO 02/90002 A2, str.
an engraved line, should preferably exceed the thickness of the said sheet or web. 
ugravirane crte, poželjno treba biti veća od debljine navedenog lista ili tkanine.
A pharmaceutical composition comprising a compound of any one of embodiments 1-80 or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav koji sadrži spoj bilo kojeg oblika 1-80 ili njihove farmaceutski prihvatljive soli
A compound according to any of claims 1 to 9, wherein W is NR7 and wherein R7 and R5 together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted pyrrolidine group. 
Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time, što je W NR; i gdje R; i Rs skupa sa odgovarajućim N atomom i C atomom za koje su prikačeni formiraju supstituiranu ili nesupstituiranu pirolidinsku grupu.
"caramel", "caramel colour", "caramel extract" or "caramel isolate". 
"karamela", "boja od karamele", "ekstrakt karamele" ili "izolat karamele".
In the third step the ethyl (4-pyridin-2-ylphenyl)acetate is saponified to the (4-pyridin-2-ylphenyl)acetic acid with about 95% yield of theory. 
B* N pri čemu R* predstavlja grupu koja se otcjepljuje pod osnovnim uvjetima zbog izravnog dobivanja (4-piridin-2-ilfenil) octene kiseline koja se nadalje pročišćava.
The tow bar holder of claim 1, wherein at least one of the retaining elements is releasably connected with the receiving elements to prevent the feet of the tow bar from slipping out of the receiving spaces. The tow bar holder of claim 2, wherein the retaining element is arranged transversely or longitudinally with respect to the receiving element. 
Držač šipke za tegljenje prema zahtjevu 1, naznačen time da je barem jedan element za zadržavanje (38) predviđen da je odvojivo spojen sa elementima za prihvat (30), pri čemu element za zadržavanje spriječava izvlačenje noge šipke za tegljenje (14) iz prihvatnog prostora (32).
a)—Moving the milling machine to a place of use specified in advance; 
premještanje glodalice (100) na unaprijed određeno radno mjesto (EO, EO1);
The application also discloses a packaging adapted to store an element, the packaging comprising one or more outer parts and one inner part, the inner part comprising a first side and a second side interconnected by a hinging part, and wherein an outer part is attached to the first and/or second side, respectively. 
Prijava također otkriva pakiranje koje je prilagođeno za pohranjivanje elementa, kojemu unutarnji dio sadržava prvu stranu i drugu stranu koje su međusobno spojene zglobnim dijelom, i kod kojega je vanjski dio pričvršćen na prvu i/ili na drugu stranu.
Italian patent application no. 
Broj europske prijave patenta:
The invention further relates to a group of container assemblies. In an embodiment, the container assemblies are stacked in layers on a pallet, such as a Europallet or block pallet, and juxtaposed assemblies in a, preferably all, layers abut, and optionally interlock, at their polygonal cross-sections. 
Skupina sklopova spremnika (1) prema zahtjevu 10, naznačena time što su sklopovi spremnika (1) složeni u slojevima na paleti (25) i naslagani sklopovi (1) u sloju se naslanjaju na njihovim poligonalnim poprečnim presjecima.
Example 14: Competition ELISA to demonstrate the ability of peptides to compete directly with human NOGO-5+6 for binding to NOGO H28L16 
Slika 19: Kompeticijska ELISA radi uspoređivanja vezanja NOGO-5+6 (GST-NOGO-A 5+6) | pepiidnih fragmenata na H28L16.
For avoidance of any doubt, whenever one of the above embodiments refers to “peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ”, said X-ray powder diffraction diagram is obtained by using using combined Cu Ka1 and Ka2 radiation, without Ka2 stripping; and it should be understood that the accuracy of the 2θ values as provided herein is in the range of +/−0.1-0.2°. 
1 24,5", dok se navedeni dijagram difrakcije praha X-zraka dobiva pomoću uporabe kombinirane radijacije Cu Kal i Cu Ka2, bez Koa2-strippinga; a preciznost za 20-vrijednosti leži u rasponu od 20 +/- 0,2".
Glutamate Salt of the Compound of Formula I 
Broj objave europskog patenta:
A salt according to any one of the preceding claims, wherein the amine contains two or more hydroxyl and/or one or more carboxylic groups. 
Sol prema jednom od prethodnih zahtjeva, naznačena time, što amin sadrži jednu ili više hidroksilnih i/ili jednu ili više karboksilnih grupa.
The pharmaceutically acceptable transdermal composition of claim 10, wherein (i) the composition has about 0.5 to about 7.5 weight percent octanol; and/or (ii) the composition has about 0.25 to about 5 weight percent limonene. 
Farmaceutski prihvatljiv transdermalni sastav iz bilo kojeg zahtjeva od 6 do 11, naznačeno time da (i) sastav ima između otprilike 0,5 i otprilike 7,5 posto težine oktanola; i/ili (11) sastav ima između otprilike 0,25 1 otprilike 5 posto težine limonena.
A method according to claim 3, comprising administering a compound according to Formula IIIa, or pharmaceutically acceptable salt thereof, wherein L1 is absent or is —O—; and W is C1-4 alkylene, or C2-4 alkenylene having one double bond. 
Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 3, naznačen time što je spoj u skladu s Formulom IIIa, a L1 je odsutan ili je -O-; W je C1-4 alkilen, ili C2-4 alkenilen s jednom dvostrukom vezom.
The antibody or antigen binding portion thereof according to any one of claims 1-6, wherein the antibody is a bispecific or multispecific antibody which specifically binds to a first antigen comprising BST1 and a second antigen selected from the group consisting of CD3 antigen and CD5 antigen. 
Protutijelo ili njegov antigen-vezujući dio sukladno bilo kojem od patentnih zahtjeva 1-6, pri tome je protutijelo bispecifično ili multispecifično protutijelo koje se specifično veže za prvi antigen koji sadrži BSTI i drugi antigen odabran iz skupine sastavljene od CD3 antigena i CD5 antigena.
4 shows an apparatus for the implementation of the method for intensification of production of high-viscosity oils using common cord and inductors. 
Slika 4 prikazuje uređaj za primjenu postupka povećanja proizvodnje naftu visoke viskoznosti uporabom zajedničkog kabla 1 induktora.
(a3) Serine (S) at heavy chain amino acid position 12; (b3) Serine (S) at heavy chain amino acid position 103; and 
(b) -glutaminska kiselina (E) na aminokiselinskoj poziciji 83 slabog lanca; (Cc) arginin (R) na aminokiselinskoj poziciji 43 jakog lanca;
The pharmaceutical composition of Claim 16 further comprising at least one additional pharmaceutical agent wherein said at least one additional pharmaceutical agent is an anticancer agent, chemotherapy agent, or antiproliferative compound. 
Farmaceutski sastav prema zahtjevu 16, naznačen time, da nadalje obuhvaća barem jedno dodatno farmaceutsko sredstvo pri čemu navedeno barem jedno farmaceutsko sredstvo je protutumorsko sredstvo, kemoterapeutsko sredstvo ili antiproliferativni spoj.
reacting a 2-keto-3-phenylaminoacrylonitrile of formula 1: with a hydrazine of formula 2: to provide a compound of formula (I) where R1 is hydrogen; or 
reagiranje 2-keto-3-fenilaminoakrilonitrila formule 1: [image] s hidrazinom formule 2: [image] za dobivanje spoja formule (I) gdje R1 je vodik; ili
Useful lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, hydrogenated castor oil, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, zinc stearate, talc, microcrystalline cellulose, and sucrose esters. 
Kruta oralna farmaceutska formulacija prema zahtjevu 1, naznačena time što je lubrikant odabran iz skupine koja sadrži magnezijev stearat, kalcijev stearat, gliceril monostearat, hidrogenirano ricinusovo ulje, natrijev lauril sulfat, natrijev stearil fumarat, stearinsku kiselinu, cinkov stearat, talk, mikrokristalnu celulozu, te estere saharoze.
The solid formulation according to claim 5, characterized in that the lactose consists of coarse particles greater than 200 µm in size. 
Kruti pripravak prema zahtjevu 4, naznačen time, da se laktoza sastoji od grubih čestica većih od 200 um.
kurstaki, nucleopolyhedrovirus, an encapsulated delta-endotoxin of Bacillus thuringiensis, baculovirus, entomopathogenic bacteria, entomopathogenic virus and entomopathogenic fungi. 
kurstaki, nukleopoliedrovirus, inkapsulirani delta-endotoksin Bacillus thuringtensis, bakulovirus, entomopatogene bakterije, entomopatogeni virus i entomopatogene gljive.
rinsing. The method as claimed in claim 9, characterized in that the leaving to act in step b) occurs at room temperature to 55° C. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što se reakcija u koraku b) odvija na sobnoj temperaturi do 55 °C, poželjno na 35 do 50 °C, poželjnije na 40 do 50 °C.
A pharmaceutical composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 30 and a pharmaceutically acceptable carrier or excipient. A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 30 . An in vitro method for inhibiting VR1 function in a cell comprising: 
Postupak za pripremu sastava, naznačen time, da se sastoji od stupnja miješanja spoja prema patentnom zahtjevu 1 ili njegove farmaceutski prihvatljive soli i farmaceutski prihvatljivog nosača ili ekscipijenta, Postupak za inhibiranje VR1 funkcije u stanici, naznačen time, da se sastoji od in vitro dovođenja u dodir stanice, sposobne da eksprimira VRI, s učinkovitom količinom spoja iz patentnog zahtjeva 1 ili njegove farmacoutski prihvatljive soli.
The composition for use of any preceding claim, wherein the plurality of liposomes comprises unilamellar vesicles, multilamellar vesicles, or a mixture thereof. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 4, naznačen time, što liposom sadrži jednolamelarne vezikule, višelamelarne vezikule, ili njihovu mješavinu.
reducing Compound 3 to yield Compound 4: and reacting Compound 4 with Compound 6: to produce Compound 2, 
CONRsRe i (c) reakciji Spoja 4 sa Spojem 6: kako bi se dobilo Spoj 2, gdje:
to obtain a compound of formula IVa in the form of diastereoisomeric mixture (S,R+R,R) wherein Y is defined above; 
Ž za dobivanje spoja formule IVa u obliku dijastereoizomerne smjese (S, R+R, R), u ce d)
2 respectively, wherein each of said regions comprises at least 4 or 5 amino acids and wherein said assay is not a manual coated-tube-Akridiniumester sandwich assay. 
2, gdje svakoje od navedenih područja sadrži najmanje 4 ili 5 aminokiselina, te gdje navedeni test nije manualni sendvič test s epruvetama obloženim akridinijevim esterom.
An alternative embodiment of the invention reltes to a bispecific single chain antibody comprising a first domain binding domain capable of binding to CD3 epsilon (CD3e) of human and non-chimpanzee primate and a second domain binding domain capable of binding to the extracellular domain of the mutated human PSMA having an amino acid sequence as depicted in SEQ ID NO: 447 but not to the extracellular domain of the rodent PSMA. 
(a) vežuća domena, koja se može vezati na izvanstaničnu domenu mutiranog ljudskog PSMA s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 447, gdje su aminokiselinski ostaci na položajima 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 7171721 mutirani u odgovarajuće aminokiselinske ostatke PSMA divljeg tipa glodavca, no ne i na izvanstaničnu domenu PSMA glodavca;
a second conductive surface opposite the first conductive surface, 
drugu provodnu površinu nasuprot prvoj provodnoj površini,